Valeritas’ V-Go wearable insulin delivery device helped to improve blood glucose levels and reduce insulin dose in type 2 diabetes patients switched from insulin pens and syringes.
The device has showed significant clinical benefits in patients with type 2 diabetes in the effectiveness of V-Go wearable insulin delivery for basal-bolus therapy (ENABLE) study.
Valeritas’ first ENABLE study poster assessed the clinical benefits in patients with type 2 diabetes who switched from using insulin pens and syringes to deliver their insulin regimen with V-Go for insulin delivery.
The 283 patient and retrospective study showed clinically and statistically significant reductions in A1C by over 1% and insulin total daily dose (TDD) at three and seven months.
The second analysis from the ENABLE study demonstrated that V-Go provided a clinical benefit to the patient population, who are poorly controlled on conventional basal-bolus therapy delivered by multiple daily injections (MDI) using insulin pens and syringes.
The analysis in 186 patients with type 2 diabetes showed reducing of A1C by -1.0 at three months, which was maintained at seven months and statistically significant with a P<0.0001.
Valeritas’ third ENABLE study poster assessed the impact of duration of diabetes on change in A1C and insulin TDD when switching patients with type 2 diabetes from insulin delivery through insulin pen or syringe to V-Go.
Based on duration of diabetes, the patients with known duration of diabetes have been stratified into five groups.
Clinically and statistically significant reductions in A1C from baseline at both three and seven-month intervals have been observed in all five duration of diabetes strata, said the company.
Valeritas CEO, John Timberlake said: “The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose.
“We recently reported our third consecutive quarter of record revenue which is a direct result of V-Go gaining momentum among patients with type 2 diabetes. V-Go is discreet, simple-to-use, cost-effective, clinically proven, and the only disposable, daily insulin delivery option.”